Recombinant anticoagulant factors for adjunctive treatment of sepsis

Seminars in Thrombosis and Hemostasis

Volumn 36, Issue 5, 2010, Pages 550-557

  Levi, Marcel ^a,b   Lowenberg, Ester ^a,b   Meijers, Joost C ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

activated protein C; antithrombin; disseminated intravascular coagulation; Sepsis; thrombomodulin; tissue factor pathway inhibitor

Indexed keywords

DROTRECOGIN; RECOMBINANT ANTITHROMBIN III; RECOMBINANT THROMBOMODULIN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; ANTICOAGULANT AGENT; RECOMBINANT PROTEIN;

ANTICOAGULATION; CLINICAL EVALUATION; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; HUMAN; PRIORITY JOURNAL; REVIEW; SEPSIS; BLOOD; BLOOD CLOTTING; DRUG EFFECTS; INFLAMMATION; PATHOLOGY;

ANTICOAGULANTS; BLOOD COAGULATION; HUMANS; INFLAMMATION; RECOMBINANT PROTEINS; SEPSIS;

EID: 77954883422     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0030-1255449     Document Type: Review

References (62)

1. Levi M, van der Poll T. The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients. Semin Thromb Hemost 2008 34 (5) 459-468
2. Levi M, Nieuwdorp M, van der Poll T, Stroes E. Metabolic modulation of inflammation-induced activation of coagulation. Semin Thromb Hemost 2008 34 (1) 26-32
3. Levi M, van der Poll T, Büller H R. Bidirectional relation between inflammation and coagulation. Circulation 2004 109 (22) 2698-2704
4. Kobayashi M, Shimada K, Ozawa T. Human recombinant interleukin-1 beta- and tumor necrosis factor alpha-mediated suppression of heparin-like compounds on cultured porcine aortic endothelial cells. J Cell Physiol 1990 144 (3) 383-390
5. Levi M, Schouten M, van der Poll T. Sepsis, coagulation, and antithrombin: old lessons and new insights. Semin Thromb Hemost 2008 34 (8) 742-746
6. Esmon C T. Role of coagulation inhibitors in inflammation. Thromb Haemost 2001 86 (1) 51-56
7. Levi M, de Jonge E, van der Poll T. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Med 2001 29 (7, Suppl) S90-S94
8. Mesters R M., Mannucci P M., Coppola R, Keller T, Ostermann H, Kienast J. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood 1996 88 (3) 881-886
9. Fourrier F, Chopin C, Goudemand J et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992 101 (3) 816-823
10. Minnema M C., Chang A C., Jansen P M. et al. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 2000 95 (4) 1117-1123
11. Bernard G R., Vincent J L., Laterre P F. et al, Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001 344 (10) 699-709
12. Levi M, de Jonge E, van der Poll T, ten Cate H. Disseminated intravascular coagulation. Thromb Haemost 1999 82 (2) 695-705
13. Warren B L., Eid A, Singer P et al, KyberSept Trial Study Group. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001 286 (15) 1869-1878
14. Blauhut B, Kramar H, Vinazzer H, Bergmann H. Substitution of antithrombin III in shock and DIC: a randomized study. Thromb Res 1985 39 (1) 81-89
15. Levi M. The diagnosis of disseminated intravascular coagulation made easy. Neth J Med 2007 65 (10) 366-367
16. Kienast J, Juers M, Wiedermann C J. et al, KyberSept investigators. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006 4 (1) 90-97
17. Morrow T. Transgenic goats are key to antithrombin production. Manag Care 2009 18 (3) 46-47
18. Edmunds T, Van Patten S M., Pollock J et al. Transgenically produced human antithrombin: structural and functional comparison to human plasma-derived antithrombin. Blood 1998 91 (12) 4561-4571
19. Berry L R., Thong B, Chan A K. Comparison of recombinant and plasma-derived antithrombin biodistribution in a rabbit model. Thromb Haemost 2009 102 (2) 302-308
20. Hirose M, Tsukada M, Hirayama F et al. Recombinant human antithrombin expressed in Chinese hamster ovary cells shows in vivo efficacy on rat DIC model similarly to plasma-derived antithrombin regardless of different N-glycosylation. Thromb Res 2007 119 (5) 631-641
21. Yang H, Li Q W., Han Z S. et al. Recombinant human antithrombin expressed in the milk of non-transgenic goats exhibits high efficiency on rat DIC model. J Thromb Thrombolysis 2009 28 (4) 449-457
22. Avidan M S., Levy J H., Scholz J et al. A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. Anesthesiology 2005 102 (2) 276-284
23. Griffin J H., Fernandez J A., Gale A J., Mosnier L O. Activated protein C. J Thromb Haemost 2007 5 (suppl 1) 73-80
24. Esmon C T. The regulation of natural anticoagulant pathways. Science 1987 235 (4794) 1348-1352
25. Esmon C T. The endothelial cell protein C receptor. Thromb Haemost 2000 83 (5) 639-643
26. Mesters R M., Helterbrand J, Utterback B G. et al. Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit Care Med 2000 28 (7) 2209-2216
27. Vary T C., Kimball S R. Regulation of hepatic protein synthesis in chronic inflammation and sepsis. Am J Physiol 1992 262 (2 Pt 1) C445-C452
28. Eckle I, Seitz R, Egbring R, Kolb G, Havemann K. Protein C degradation in vitro by neutrophil elastase. Biol Chem Hoppe Seyler 1991 372 (11) 1007-1013
29. Nawroth P P., Stern D M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986 163 (3) 740-745
30. Faust S N., Levin M, Harrison O B. et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001 345 (6) 408-416
31. Taylor F BJ Jr, Stearns-Kurosawa D J., Kurosawa S et al. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood 2000 95 (5) 1680-1686
32. de Pont A C., Bakhtiari K, Hutten B A. et al. Endotoxaemia induces resistance to activated protein C in healthy humans. Br J Haematol 2006 134 (2) 213-219
33. Levi M. Activated protein C in sepsis: a critical review. Curr Opin Hematol 2008 15 (5) 481-486
34. Laterre P F. Clinical trials in severe sepsis with drotrecogin alfa (activated). Crit Care 2007 11 (suppl 5) S5
35. Levi M, De Jonge E, van der Poll T. Recombinant human activated protein C (Xigris). Int J Clin Pract 2002 56 (7) 542-545
36. Bernard G R., Ely E W., Wright T J. et al. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 2001 29 (11) 2051-2059
37. Taylor F BJ Jr, Toh C H., Hoots W K., Wada H, Levi M, Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001 86 (5) 1327-1330
38. Dhainaut J F., Yan S B., Joyce D E. et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004 2 (11) 1924-1933
39. Ely E W., Laterre P F., Angus D C. et al, PROWESS Investigators. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003 31 (1) 12-19
40. Abraham E, Laterre P F., Garg R et al, Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005 353 (13) 1332-1341
41. Levi M, Levy M, Williams M D. et al, Xigris and Prophylactic HepaRin Evaluation in Severe Sepsis (XPRESS) Study Group. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med 2007 176 (5) 483-490
42. Bijsterveld N R., Moons A H., Meijers J C. et al. Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin. J Am Coll Cardiol 2002 39 (5) 811-817
43. Levy M, Levi M, Williams M D., Antonelli M, Wang D, Mignini M A. Comprehensive safety analysis of concomitant drotrecogin alfa (activated) and prophylactic heparin use in patients with severe sepsis. Intensive Care Med 2009 35 (7) 1196-1203
44. Dellinger R P., Levy M M., Carlet J M. et al, International Surviving Sepsis Campaign Guidelines Committee American Association of Critical-Care Nurses American College of Chest Physicians American College of Emergency Physicians Canadian Critical Care Society European Society of Clinical Microbiology and Infectious Diseases European Society of Intensive Care Medicine European Respiratory Society International Sepsis Forum Japanese Association for Acute Medicine Japanese Society of Intensive Care Medicine Society of Critical Care Medicine Society of Hospital Medicine Surgical Infection Society World Federation of Societies of Intensive and Critical Care Medicine. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008 36 (1) 296-327
45. Wiedermann C J., Kaneider N C. A meta-analysis of controlled trials of recombinant human activated protein C therapy in patients with sepsis. BMC Emerg Med 2005 5 7
46. Martí-Carvajal A, Salanti G, Cardona A F. Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev 2007 (3) CD004388
47. Fumagalli R, Mignini M A. The safety profile of drotrecogin alfa (activated). Crit Care 2007 11 (Suppl 5) S6
48. Wheeler A, Steingrub J, Schmidt G A. et al. A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial. Crit Care Med 2008 36 (1) 14-23
49. Bernard G R., Margolis B D., Shanies H M. et al, Extended Evaluation of Recombinant Human Activated Protein C United States Investigators. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis. Chest 2004 125 (6) 2206-2216
50. Schultz M J., Levi M. Prescription of rh-APC differs substantially among western European countries. Intensive Care Med 2006 32 (4) 630-631
51. Barie P S. All in for a huge pot: the PROWESS-SHOCK trial for refractory septic shock. Surg Infect (Larchmt) 2007 8 (5) 491-494
52. Esmon C T. New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins. J Exp Med 2002 196 (5) 561-564
53. Zushi M, Gomi K, Yamamoto S, Maruyama I, Hayashi T, Suzuki K. The last three consecutive epidermal growth factor-like structures of human thrombomodulin comprise the minimum functional domain for protein C-activating cofactor activity and anticoagulant activity. J Biol Chem 1989 264 (18) 10351-10353
54. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996 271 (28) 16603-16608
55. Campbell W, Okada N, Okada H. Carboxypeptidase R is an inactivator of complement-derived inflammatory peptides and an inhibitor of fibrinolysis. Immunol Rev 2001 180 162-167
56. Conway E M., Van de Wouwer M, Pollefeyt S et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med 2002 196 (5) 565-577
57. Hagiwara S, Iwasaka H, Matsumoto S, Hasegawa A, Yasuda N, Noguchi T. In vivo and in vitro effects of the anticoagulant, thrombomodulin, on the inflammatory response in rodent models. Shock 2010 33 (3) 262-268
58. Saito H, Maruyama I, Shimazaki S et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007 5 (1) 31-41
59. de Jonge E, Dekkers P E., Creasey A A. et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 2000 95 (4) 1124-1129
60. Creasey A A., Chang A C., Feigen L, Wün T C., Taylor F BJ Jr, Hinshaw L B. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993 91 (6) 2850-2860
61. Abraham E, Reinhart K, Svoboda P et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001 29 (11) 2081-2089
62. Abraham E, Reinhart K, Opal S et al, OPTIMIST Trial Study Group. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003 290 (2) 238-247